English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17918/22935 (78%)
Visitors : 6794592      Online Users : 158
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/25117


    Title: Treatment of hepatitis C with direct-acting antiviral agents in renal transplant recipients: a long-term and real-world experience
    Authors: Lian, Sheng-Wen Wu ; Chi-Chih Wang ; Ming-Chang Tsai ; Jong-Da
    Contributors: 中山醫學大學
    Date: 2022-06-01
    Issue Date: 2022-10-21T03:21:09Z (UTC)
    Publisher: 研發處育成中心暨產學合作組
    Abstract: Purpose: Direct- acting antivirals (DAAs) are showing encouraging results in hepatitis C virus (HCV) eradication and drug safety, but limited data exist for renal transplant recipients (RTRs). In addition, data are lacking regarding the outcomes of RTRs who failed a previous DAA regimen. Method: We collected data from 17 consecutive HCV-infected RTRs treated with DDAs to evaluate DAA efficacy, relevant side effects, and long-term patient outcomes. Initial DAA regimens included sofosbuvir (SOF)-based regimens in 16 patients (94%) and daclatasvir plus asunaprevir in 1 patient. Results: All patients exhibited a rapid virologic response to therapy and 14 patients (82.3%) achieved a sustained virologic response at 12 weeks after the end of therapy. The anti-HCV regimens were well tolerated, but the tacrolimus level decreased significantly at 2 weeks after treatment. Two RTRs with prior DAA failure were successfully retreated with SOF plus velpatasvir (VEL). Conclusions: IFN-free DAAs were efficacious and well-tolerated in our Asian RTRs. Patients should be carefully monitored to avoid sub-therapeutic immunosuppression in routine practice, regardless of DAA regimens. This is a first report that the combination of SOF and VEL is apparently effective and well-tolerated in RTRs with prior DAAs failure. Further studies are needed to verify our findings.
    URI: https://ir.csmu.edu.tw:8080/handle/310902500/25117
    Relation: 中山醫學雜誌 ; 33卷1期 (2022 / 06 / 01) , P9 - 16
    Appears in Collections:[研發處] 期刊論文

    Files in This Item:

    File Description SizeFormat
    Treatment of hepatitis C with direct-acting antiviral agents in renal transplant recipients a long-t.pdf530KbAdobe PDF125View/Open


    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback